A
NVS icon

Astrantus’s Novartis NVS Stock Holding History

Astrantus’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$483K Sell
5,500
-5,061
-48% -$438K 0.81% 5
2021
Q4 		$924K Buy
+10,561
New +$877K 0.69% 53

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Astrantus's NVS Position: Q1 2022 in Review

Astrantus reduced its Novartis (NVS) stake by 48% in Q1 2022, selling an estimated $438K and leaving 5,500 shares worth $483K. The position accounts for 0.81% of the portfolio, ranked #5.

Astrantus first reported a position in NVS in Q4 2021 and has held it in 2 quarters since. The position peaked at $924K in Q4 2021. 1,137 funds tracked by Wall St. Rank hold NVS as of Q1 2022.

  • Astrantus held 5,500 shares of Novartis worth $483K as of Q1 2022.
  • Astrantus sold 5,061 Novartis shares in Q1 2022, an estimated $438K.
  • Novartis made up 0.81% of Astrantus's portfolio in Q1 2022, its #5 holding.
  • Astrantus first reported a position in Novartis in Q4 2021 and has held it in 2 quarters since.
  • Astrantus's Novartis position peaked at $924K in Q4 2021.
  • 1,137 funds tracked by Wall St. Rank held Novartis as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.